Pre-operative Olanzapine as Prophylactic Antiemetic in Oncologic Patients

Postoperative Nausea and Vomiting Clinical Trial

Official title:

Pre-operative Olanzapine as Prophylactic Antiemetic in Oncologic Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03631004
• Other study ID #: 1287/18
• Status: Completed
• Phase: Phase 2/Phase 3
• Start date: October 1, 2018
• Est. completion date: February 10, 2021

Study information

• Verified date: December 2021
• Source: Instituto do Cancer do Estado de São Paulo
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Olanzapine has been used as prophylactic antiemetic for chemotherapy induced nausea and vomiting. The project aims to evaluate the efficacy of olanzapine in combination with ondansetron and dexamethasone in patients at high risk of postoperative nausea and vomiting, with previous history of nausea and vomiting induced by prior chemotherapy, submitted to medium and large surgery.

Description:

Double blinded randomized clinical trial. Fifty patients will be selected for each group. Group A will receive 10mg olanzapine in the preoperative and group B will receive placebo in the preoperative period. Both groups will receive intravenous general anesthesia combined with epidural. All patients will receive epidural PCA. The primary outcome of this study is the incidence of post-operative nausea and vomiting. The power of analysis was based on the following parameters: type error I (α = 0.05), error II (β = 0.8), 95% confidence interval and hypothesis test two-tailed. Thus, 42 patients are indicated per group to obtain reduction of the incidence of nausea and / or vomiting of the population risk from 60% to 30%. The population will be composed of 100 patients because it is assumed that percentage of loss of 10% per group. The statistical analysis will be performed in program R version 3.5.1. The results obtained will be presented as mean + standard deviation for continuous data or absolute frequency for described data. For quantitative variables, the Student's t-test will be used for with normal distribution or Mann-Whitney for non-distributed data normal. For qualitative variables, the chi-square test will be used or Fisher's exact test. Significant difference is defined as p, 0.05. Data will be collected and managed using REDCap data capture tools

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: February 10, 2021
• Est. primary completion date: February 10, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion criteria:

• Patients submitted to medium and large surgeries in the thoracic or abdominal region (mastectomies, breast plastic, hysterectomies, annexectomies, gynecological pelvic surgeries, colectomies, rettosigmoidectomies) under general anesthesia
• Patients aged between 18 and 60 years
• Patients considered to be at high risk for PONV according to the Apfel scale (Apfel 3 or 4)
• Patients with a history of chemotherapy-induced nausea and vomiting.

Exclusion criteria:

• Pregnancy or Lactation
• Current use of typical anti-psychotic medications or atypical
• History of allergy to olanzapine
• Myocardial infarction or unstable angina in the 6 months prior to the day of surgery planning
• History of severe ventricular arrhythmia (eg, VT or VF)
• Heart Failure Class II or greater second NYHA
• Postural hypotension or vasovagal syncope in the 6 months prior to the day of surgery planning
• Narrow angle glaucoma
• Parkinson's disease
• Dementia
• Inability to swallow medicines
• QT interval history greater than 450ms or torsades de pointes
• Patient does not want to participate in the study
• Videolaparoscopy surgery
• Contraindication for neuraxial block

Related Conditions & MeSH terms

• Nausea
• Postoperative Nausea
• Postoperative Nausea and Vomiting
• Vomiting

Intervention

Drug:
• Olanzapine
olanzapine 10 mg is given before surgery

Locations

Country	Name	City	State
Brazil	Cancer Institute of the State of Sao Paulo - ICESP	Sao Paulo	São Paulo

Sponsors (1)

Lead Sponsor	Collaborator
Instituto do Cancer do Estado de São Paulo

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	incidence of postoperative nausea and vomiting	nausea and vomiting/ retching (dichotomous variable)	0-24 hours
Secondary	incidence of side effects	side effects	0-6 hours
Secondary	incidence of side effects	side effects	0-24 hours
Secondary	incidence of side effects	side effects	24-48 hours
Secondary	incidence of postoperative nausea and vomiting	nausea and vomiting/ retching (dichotomous variable)	0-6 hours
Secondary	incidence of postoperative nausea and vomiting	nausea and vomiting/ retching (dichotomous variable)	24-48 hours
Secondary	incidence of postoperative nausea	nausea and vomiting/ retching (dichotomous variable)	0-6 hours
Secondary	incidence of postoperative nausea	nausea and vomiting/ retching (dichotomous variable)	0-24 hours
Secondary	incidence of postoperative nausea	nausea and vomiting/ retching (dichotomous variable)	24-48 hours
Secondary	incidence of postoperative vomiting/retching	vomiting/ retching (dichotomous variable)	0-6 hours
Secondary	incidence of postoperative vomiting/retching	vomiting/ retching (dichotomous variable)	0-24 hours
Secondary	incidence of postoperative vomiting/retching	vomiting/ retching (dichotomous variable)	24-48 hours
Secondary	incidence of severe PONV	This scale consists of four questions. Each question generates a different score. For the first question, if the patient vomited or retched three or more times, the final score was 50. Otherwise, the highest score from question 1 or question 2 was multiplied by the scores of question 3 and question 4, yielding the final value. When the score was = 50, the symptom was considered clinically important.	0-6 hours
Secondary	incidence of severe PONV	This scale consists of four questions. Each question generates a different score. For the first question, if the patient vomited or retched three or more times, the final score was 50. Otherwise, the highest score from question 1 or question 2 was multiplied by the scores of question 3 and question 4, yielding the final value. When the score was = 50, the symptom was considered clinically important.	0-24 hours
Secondary	incidence of severe PONV	This scale consists of four questions. Each question generates a different score. For the first question, if the patient vomited or retched three or more times, the final score was 50. Otherwise, the highest score from question 1 or question 2 was multiplied by the scores of question 3 and question 4, yielding the final value. When the score was = 50, the symptom was considered clinically important.	24-48 hours
Secondary	incidence of nausea severity	mild, moderate, or severe	0-6 hours
Secondary	incidence of nausea severity	mild, moderate, or severe	0-24 hours
Secondary	incidence of nausea severity	mild, moderate, or severe	24-48 hours